Alternative activation of human plasmacytoid DCs in vitro and in melanoma lesions: Involvement of LAG-3

Chiara Camisaschi, Annamaria De Filippo, Valeria Beretta, Barbara Vergani, Antonello Villa, Elisabetta Vergani, Mario Santinami, Antonello Domenico Cabras, Flavio Arienti, Frédéric Triebel, Monica Rodolfo, Licia Rivoltini, Chiara Castelli

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Plasmacytoid dendritic cells (pDCs) at tumor sites are often tolerogenic. Although pDCs initiate innate and adaptive immunity upon Toll-like receptor (TLR) triggering by pathogens, TLR-independent signals may be responsible for pDC activation and immune suppression in the tumor inflammatory environment. To identify molecules that are potentially involved in alternative pDC activation, we explored the expression and function of lymphocyte activation gene 3 (LAG-3) in human pDCs. In this report, we showed the expression of LAG-3 on the cell surface of a subset of circulating human pDCs. LAG-3+ pDCs exhibited a partially mature phenotype and were enriched at tumor sites in samples from melanoma patients. We found that LAG-3 interacted with major histocompatibility complex class II (MHC-II) to induce TLR-independent activation of pDCs with limited IFNα and enhanced IL-6 production. This in vitro cytokine profile of LAG-3-activated pDCs paralleled that of tumor-associated pDCs analyzed ex vivo. By confocal microscopy, LAG-3+ pDCs detected in melanoma-invaded lymph nodes (LNs) stained positive for IL-6 and preferentially localized near melanoma cells. These results suggest that LAG-3-mediated activation of pDCs takes place in vivo at tumor sites, and it is in part responsible for directing an immune-suppressive environment.

Original languageEnglish
Pages (from-to)1893-1902
Number of pages10
JournalJournal of Investigative Dermatology
Volume134
Issue number7
DOIs
Publication statusPublished - 2014

Fingerprint

Lymphocytes
Lymphocyte Activation
Dendritic Cells
Melanoma
Genes
Chemical activation
Tumors
Toll-Like Receptors
Neoplasms
Interleukin-6
In Vitro Techniques
Adaptive Immunity
Confocal microscopy
Major Histocompatibility Complex
Innate Immunity
Pathogens
Confocal Microscopy
Lymph Nodes
Cytokines
Phenotype

ASJC Scopus subject areas

  • Dermatology
  • Biochemistry
  • Cell Biology
  • Molecular Biology

Cite this

Alternative activation of human plasmacytoid DCs in vitro and in melanoma lesions : Involvement of LAG-3. / Camisaschi, Chiara; De Filippo, Annamaria; Beretta, Valeria; Vergani, Barbara; Villa, Antonello; Vergani, Elisabetta; Santinami, Mario; Cabras, Antonello Domenico; Arienti, Flavio; Triebel, Frédéric; Rodolfo, Monica; Rivoltini, Licia; Castelli, Chiara.

In: Journal of Investigative Dermatology, Vol. 134, No. 7, 2014, p. 1893-1902.

Research output: Contribution to journalArticle

Camisaschi, Chiara ; De Filippo, Annamaria ; Beretta, Valeria ; Vergani, Barbara ; Villa, Antonello ; Vergani, Elisabetta ; Santinami, Mario ; Cabras, Antonello Domenico ; Arienti, Flavio ; Triebel, Frédéric ; Rodolfo, Monica ; Rivoltini, Licia ; Castelli, Chiara. / Alternative activation of human plasmacytoid DCs in vitro and in melanoma lesions : Involvement of LAG-3. In: Journal of Investigative Dermatology. 2014 ; Vol. 134, No. 7. pp. 1893-1902.
@article{566ebe8278504312a8eeefb84aa891e3,
title = "Alternative activation of human plasmacytoid DCs in vitro and in melanoma lesions: Involvement of LAG-3",
abstract = "Plasmacytoid dendritic cells (pDCs) at tumor sites are often tolerogenic. Although pDCs initiate innate and adaptive immunity upon Toll-like receptor (TLR) triggering by pathogens, TLR-independent signals may be responsible for pDC activation and immune suppression in the tumor inflammatory environment. To identify molecules that are potentially involved in alternative pDC activation, we explored the expression and function of lymphocyte activation gene 3 (LAG-3) in human pDCs. In this report, we showed the expression of LAG-3 on the cell surface of a subset of circulating human pDCs. LAG-3+ pDCs exhibited a partially mature phenotype and were enriched at tumor sites in samples from melanoma patients. We found that LAG-3 interacted with major histocompatibility complex class II (MHC-II) to induce TLR-independent activation of pDCs with limited IFNα and enhanced IL-6 production. This in vitro cytokine profile of LAG-3-activated pDCs paralleled that of tumor-associated pDCs analyzed ex vivo. By confocal microscopy, LAG-3+ pDCs detected in melanoma-invaded lymph nodes (LNs) stained positive for IL-6 and preferentially localized near melanoma cells. These results suggest that LAG-3-mediated activation of pDCs takes place in vivo at tumor sites, and it is in part responsible for directing an immune-suppressive environment.",
author = "Chiara Camisaschi and {De Filippo}, Annamaria and Valeria Beretta and Barbara Vergani and Antonello Villa and Elisabetta Vergani and Mario Santinami and Cabras, {Antonello Domenico} and Flavio Arienti and Fr{\'e}d{\'e}ric Triebel and Monica Rodolfo and Licia Rivoltini and Chiara Castelli",
year = "2014",
doi = "10.1038/jid.2014.29",
language = "English",
volume = "134",
pages = "1893--1902",
journal = "Journal of Investigative Dermatology",
issn = "0022-202X",
publisher = "Nature Publishing Group",
number = "7",

}

TY - JOUR

T1 - Alternative activation of human plasmacytoid DCs in vitro and in melanoma lesions

T2 - Involvement of LAG-3

AU - Camisaschi, Chiara

AU - De Filippo, Annamaria

AU - Beretta, Valeria

AU - Vergani, Barbara

AU - Villa, Antonello

AU - Vergani, Elisabetta

AU - Santinami, Mario

AU - Cabras, Antonello Domenico

AU - Arienti, Flavio

AU - Triebel, Frédéric

AU - Rodolfo, Monica

AU - Rivoltini, Licia

AU - Castelli, Chiara

PY - 2014

Y1 - 2014

N2 - Plasmacytoid dendritic cells (pDCs) at tumor sites are often tolerogenic. Although pDCs initiate innate and adaptive immunity upon Toll-like receptor (TLR) triggering by pathogens, TLR-independent signals may be responsible for pDC activation and immune suppression in the tumor inflammatory environment. To identify molecules that are potentially involved in alternative pDC activation, we explored the expression and function of lymphocyte activation gene 3 (LAG-3) in human pDCs. In this report, we showed the expression of LAG-3 on the cell surface of a subset of circulating human pDCs. LAG-3+ pDCs exhibited a partially mature phenotype and were enriched at tumor sites in samples from melanoma patients. We found that LAG-3 interacted with major histocompatibility complex class II (MHC-II) to induce TLR-independent activation of pDCs with limited IFNα and enhanced IL-6 production. This in vitro cytokine profile of LAG-3-activated pDCs paralleled that of tumor-associated pDCs analyzed ex vivo. By confocal microscopy, LAG-3+ pDCs detected in melanoma-invaded lymph nodes (LNs) stained positive for IL-6 and preferentially localized near melanoma cells. These results suggest that LAG-3-mediated activation of pDCs takes place in vivo at tumor sites, and it is in part responsible for directing an immune-suppressive environment.

AB - Plasmacytoid dendritic cells (pDCs) at tumor sites are often tolerogenic. Although pDCs initiate innate and adaptive immunity upon Toll-like receptor (TLR) triggering by pathogens, TLR-independent signals may be responsible for pDC activation and immune suppression in the tumor inflammatory environment. To identify molecules that are potentially involved in alternative pDC activation, we explored the expression and function of lymphocyte activation gene 3 (LAG-3) in human pDCs. In this report, we showed the expression of LAG-3 on the cell surface of a subset of circulating human pDCs. LAG-3+ pDCs exhibited a partially mature phenotype and were enriched at tumor sites in samples from melanoma patients. We found that LAG-3 interacted with major histocompatibility complex class II (MHC-II) to induce TLR-independent activation of pDCs with limited IFNα and enhanced IL-6 production. This in vitro cytokine profile of LAG-3-activated pDCs paralleled that of tumor-associated pDCs analyzed ex vivo. By confocal microscopy, LAG-3+ pDCs detected in melanoma-invaded lymph nodes (LNs) stained positive for IL-6 and preferentially localized near melanoma cells. These results suggest that LAG-3-mediated activation of pDCs takes place in vivo at tumor sites, and it is in part responsible for directing an immune-suppressive environment.

UR - http://www.scopus.com/inward/record.url?scp=84902547851&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84902547851&partnerID=8YFLogxK

U2 - 10.1038/jid.2014.29

DO - 10.1038/jid.2014.29

M3 - Article

C2 - 24441096

AN - SCOPUS:84902547851

VL - 134

SP - 1893

EP - 1902

JO - Journal of Investigative Dermatology

JF - Journal of Investigative Dermatology

SN - 0022-202X

IS - 7

ER -